Table 1.
An overview of targeted nanodevices for drug delivery in head and neck cancer management
| Targeting antigen | Targeting moiety antibody |
Nano-platform | Drug | Ref. |
|---|---|---|---|---|
| Folate receptor | folic acid | heparin-folic acid-paclitaxel (HFT) | paclitaxel | 113 |
| folic acid | acetylated generation 5 dendrimers | methotrexate | 114 | |
| folic acid | magnetic nanoparticles | cisplatin | 115 | |
| folic acid | Albumin | paclitaxel | 118 | |
| folic acid | Liposome (plus antisense HER-2) |
cisplatin, taxotere, doxorubicin, 5-fluorouracil |
133 | |
| EGFR | EGF | SWNTs | cisplatin | 119 |
| Cetuximab | carbon nanoparticle (ps: noncovalent assembly ) |
paclitaxel | 103 104 | |
| Mcl1 | Mcl1 siRNA | lipid nanoparticles | mitoxantrone | 123 |
| Mcl1 siRNA | lipid nanoparticles | paclitaxel | 124 | |
| Mcl1 siRNA | lipid nanoparticles | SAHA | 125 | |
| CK 2 | CK 2 siRNA | liposome | cisplatin | 56 |
| Survivin | Survivin siRNA | liposome (plus iNOS-specific inhibitor 1400W) |
paclitaxel | 134 |
Abbreviations: HFT, heparin-folic acid-paclitaxel; EGFR, epidermal growth factor receptor; EGF, epidermal growth factor receptor; HER-2, human epidermal-growth-factor receptor 2; SWNTs, single-walled carbon nanotubes; Mcl1, myeloid cell leukemia sequence 1; SAHA, suberoylanilide hydroxamic acid; iNOS, inducible NO synthase